DEFINIUM THERAPEUTICS INC (DFTX)
Health Care · Psychedelic and empathogen psychiatry therapeutics · NASDAQ
Definium is applying scientific rigor to psychedelics and empathogens to develop FDA-breakthrough-designated treatments for anxiety, depression, PTSD, and autism.
What DEFINIUM THERAPEUTICS INC does
Definium Therapeutics is a late-stage clinical biopharmaceutical company developing novel pharmaceutically optimized product candidates derived from psychedelics and empathogens to treat brain health and psychiatric disorders. The company's lead candidates are DT120 (lysergide D-tartrate/LSD) in development for generalized anxiety disorder (GAD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD), and DT402 (R(-)-MDMA) in development for autism spectrum disorder (ASD). The company is advancing multiple Phase 3 clinical trials with the goal of creating accessible psychiatric treatments.
Themes: ["psychedelic psychiatry / brain health","generalized anxiety disorder (GAD)","major depressive disorder (MDD)","post-traumatic stress disorder (PTSD)","autism spectrum disorder (ASD)","controlled substance therapeutics"]
Fundamentals
- Price$48.45 as of 2026-07-09 close
- Market cap$6.4B as of 2026-07-10
- 1-year return+527.6% as of 2026-07-09 close
- ROE-102.5% as of 2026-07-10
- Debt / equity0.15 as of 2026-07-10
- Beta2.29 as of 2026-07-10
Key risks (from latest filing)
["Regulatory risk: Advancement of product candidates depends on FDA approval and DEA scheduling decisions for Schedule I controlled substances, including potential rescheduling before marketing","Clinical trial execution risk: Multiple Phase 3 trials (Voyage, Panorama, Emerge, Ascend) depend on successful patient recruitment, site activation, and achievement of primary endpoints; failures could delay or halt development","Market acceptance and reimbursement risk: Success requires overcoming stigma and regulatory barriers around psychedelic/empathogen treatments, securing insurance coverage, and achieving clinical acceptance in psychiatry"]
Competitors & peers
- Lykos Therapeutics (MDMA-assisted therapy)
- Compass Pathways (psilocybin-assisted therapy)
- Atai Life Sciences
- Beckley Psytech
- Janssen Pharmaceuticals (esketamine / Spravato)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.